Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16383Keywords:
miRNA, renal cell carcinoma, targeted therapyAbstract
Background: Renal cell carcinoma (RCC) is one of the most common solid tumors in adults highly resistant to conventional therapies. The expression profile of a number of miRNAs correlates with RCC response to chemotherapeutic agents. Aim: To identify the association of tumor miRNAs expression with neoadjuvant treatment response in patients with RCC. Materials and Methods: We analyzed the expression levels of tumor miR-99b, -144, -155, -210, -222, -302а, -377 in 93 RCC patients who received pazopanib or sunitinib in neoadjuvant regimen using RT-PCR. RNU48 was used as a reference miRNA. Results: The levels of expression of miR-99b and -377 are associated with the RCC response to pazopanib, and microRNA-210 and -377 to sunitinib. The characteristic expression profile of miR-99b, -144, -222, -377, and miR-302a determined in 90% of cases was delineated in pazopanib responders as opposed to nonresponders. Similarly, the characteristic expression profile of miR-210, -222, -302a and -377 was suggested for sunitinib responders. Conclusions: Levels of miR-99b, -210 and -377 expression in RCC tumor tissue might be used as a basis for future predictive panel intended for the assessment of the sensitivity to the regimens of neoadjuvant RCC treatment.
References
Stakhovskyi E, Saidakova N, Vitruk Yu. et al. Nephrectomy: the state of the problem in Ukraine. Urologiya 2017; 2: 5–13 (in Ukrainian).
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.
Cancer in Ukraine, 2019–2020. Incidence, mortality, activities of oncological service. Bull Nat Cancer Registry Ukr, No. 22, Кyiv, 2020. 82 p.
Kuusk T, Szabados B, Liu WK, et al. Cytoreductive nephrectomy in the current treatment algorithm. Ther Adv Med Oncol 2019; 11: 1758835919879026.
Tanaka N, Mizuno R, Ito K, et al. External validation of the MSKCC and IMDC risk models in patients treated with targeted therapy as a first-line and subsequent second-line treatment: a Japanese multi-institutional study. Eur Urol Focus 2016; 2: 303–9.
Voylenko O, Pikul MV, Stakhovskiy O, et al. Determination of optimal term of conduction of neoadjuvant targeted therapy in patients with localized reno–cellular carcinoma. Klin Khir 2019; 86: 56–60 (in Ukrainian).
Stakhovskyi E, Vitruk Yu, Voylenko O, et al. Ways to reduce the disability of the population of Ukraine with kidney tumors. Oncourologiya 2017; 21: 51–7 (in Ukrainian).
Tang K, Xu H. Prognostic value of meta-signature miRNAs in renal cell carcinoma: an integrated miRNA expression profiling analysis. Sci Rep 2015; 5: 1–12.
Chekhun V, Lukianova N, Chekhun S, et al. Association of CD44+ CD24-/low with markers of aggressiveness and plasticity of cell lines and tumors of patients with breast cancer. Exp Oncol 2017; 39: 203–11.
Chekhun V, Borikun T, Bazas V, et al. Association of circulating miR-21, -205, and-182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment. Exp Oncol 2020; 42: 162–6.
Li M, Wang Y, Song Y, et al. MicroRNAs in renal cell carcinoma: a systematic review of clinical implications. Oncol Rep 2015; 33: 1571–8.
Kirkilevsky S, Krakhmalev P, Malyshok N, et al. Prognostic significance of microRNA-200b and ERCC1 expression in tumor cells of patients with esophageal cancer. Exp Oncol 2020; 42: 167–71.
Voylenko OA, Stakhovsky OE, Vitruk IV, et al. Efficacy of neoadjuvant targeted therapy in treatment of patients with localised clear-cell renal cell carcinoma. Adv Urol 2021; 2021: 6674637.
Kutikov A, Uzzo R. The RENAL nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009; 182: 844–53.
Shparyk Ya. Kidney cancer: latest achievements in medical treatment. Onkologiya 2008; 10: 436–42 (in Ukrainian).
Graser A, Becker C, Reiser M, et al. Volumetry of metastases from renal cell carcinoma: comparison with the RECIST criteria. Der Radiologe 2008; 48: 850–6.
Ye J, Xu M, Tian X, et al. Research advances in the detection of miRNA. J Pharm Anal 2019; 9: 217–26.
Wotschofsky Z, Meyer H, Jung M. et al. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem 2011; 417: 233–41.
Kovacova J, Juracek J, Poprach A, et al. Candidate microRNA biomarkers of therapeutic response to sunitinib in metastatic renal cell carcinoma: A validation study in patients with extremely good and poor response. Anticancer Res 2018; 38: 2961–5.
Lukamowicz-Rajska M, Mittmann C, Prummer M, et al. MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. Oncotarget 2016; 7: 78433.
Xiao W, Lou N, Ruan H, et al. Mir-144-3p promotes cell proliferation, metastasis, sunitinib resistance in clear cell renal cell carcinoma by downregulating ARID1A. Cell Physiol Biochem 2017; 43: 2420–33.
Khella H, Butz H, Ding Q, et al. miR-221/222 are involved in response to sunitinib treatment in metastatic renal cell carcinoma. Mol Ther 2015; 23: 1748–58.
D’Aniello C, Berretta M, Cavaliere C, et al. Biomarkers of prognosis and efficacy of anti-angiogenic therapy in metastatic clear cell renal cancer. Front Oncol 2019; 9: 1400.
Liu F, Chen N, Xiao R, et al. miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. Biochem Biophys Res Commun 2016; 480: 87–93.
Xiang C, Cui S, Ke Y. MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR. J Huazhong Univ Sci Technol Med Sci 2016; 36: 186–92.
Merhautova J, Hezova R, Poprach A, et al. miR-155 and miR-484 are associated with time to progression in metastatic renal cell carcinoma treated with sunitinib. BioMed Res Int 2015: 2015.
Yamada Y, Arai T, Kojima S, et al. Regulation of antitumor miR-144-5p targets oncogenes: direct regulation of syndecan-3 and its clinical significance. Cancer Sci 2018; 109: 2919–36.
McCormick RI, Blick C, Ragoussis J, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer 2013; 108: 1133–42.
Sun L, Fang Y, Wang X, et al. miR-302a inhibits metastasis and cetuximab resistance in colorectal cancer by targeting NFIB and CD44. Theranostics 2019; 9: 8409.
Wang R, Ma Y, Yu D, et al. miR-377 functions as a tumor suppressor in human clear cell renal cell carcinoma by targeting ETS1. Biomed Pharmacother 2015; 70: 64–71.
Lyu J, Zhu Y, Zhang Q. An increased level of MiR-222-3p is associated with TMP2 suppression, ERK activation and is associated with metastasis and a poor prognosis in renal clear cell carcinoma. Cancer Biomark 2020; 28: 141–9.
Zhao L, Quan J, Li Z, et al. MicroRNA-222-3p promotes tumor cell migration and invasion and inhibits apoptosis, and is correlated with an unfavorable prognosis of patients with renal cell carcinoma. Int J Mol Med 2019; 43: 525–34.
Samaan S, Khella HW, Girgis A, et al. miR-210 is a prognostic marker in clear cell renal cell carcinoma. J Mol Diagn 2015; 17: 136–44.
Lampis A, Hahne JC, Hedayat S, et al. MicroRNAs as mediators of drug resistance mechanisms. Curr Opin Pharmacol 2020; 54: 44–50.
Rosa A, Brivanlou AH. A regulatory circuitry comprised of miR-302 and the transcription factors OCT4 and NR2F2 regulates human embryonic stem cell differentiation. EMBO J 2011; 30: 237–48.
Gu DH, Mao JH, Pan XD, et al. microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2). Oncotarget 2017; 8: 26334.
Yeh I, Liu KT, Shen JH, et al. Identification of the potential prognostic markers from the miRNA-lncRNA-mRNA interactions for metastatic renal cancer via next-generation sequencing and bioinformatics. Diagnostics 2020; 10: 228.
Módos D, Bulusu KC, Fazekas D, et al. Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies. NPJ Syst Biol Appl 2017; 3: 1–13.
Lukianova NY, Borikun TV, Chekhun VF. Tumor microenvironment-derived miRNAs as prognostic markers of breast cancer. Exp Oncol 2019; 41: 242–7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
